FI103276B1 - Menetelmä terapeuttisesti käyttökelpoisten bents[g]indoli-2,3-dioni-3-hydratsonijohdannaisten ja 6,7,8,9-tetrahydrobents[g]indoli-2,3-dionihydratsonijohdannaisten valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisten bents[g]indoli-2,3-dioni-3-hydratsonijohdannaisten ja 6,7,8,9-tetrahydrobents[g]indoli-2,3-dionihydratsonijohdannaisten valmistamiseksi

Info

Publication number
FI103276B1
FI103276B1 FI921049A FI921049A FI103276B1 FI 103276 B1 FI103276 B1 FI 103276B1 FI 921049 A FI921049 A FI 921049A FI 921049 A FI921049 A FI 921049A FI 103276 B1 FI103276 B1 FI 103276B1
Authority
FI
Finland
Prior art keywords
alkyl
hydrogen
independently
benzyl
dione
Prior art date
Application number
FI921049A
Other languages
English (en)
Swedish (sv)
Other versions
FI921049A (fi
FI103276B (fi
FI921049A0 (fi
Inventor
Bjarne Hugo Dahl
Frank Waetjen
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Publication of FI921049A0 publication Critical patent/FI921049A0/fi
Publication of FI921049A publication Critical patent/FI921049A/fi
Application granted granted Critical
Publication of FI103276B1 publication Critical patent/FI103276B1/fi
Publication of FI103276B publication Critical patent/FI103276B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Holo Graphy (AREA)
  • Cephalosporin Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
FI921049A 1991-03-15 1992-03-11 Menetelmä terapeuttisesti käyttökelpoisten bents£g|indoli-2,3-dioni-3- hydratsonijohdannaisten ja 6,7,8,9-tetrahydrobents£g|indoli-2,3-dionih ydratsonijohdannaisten valmistamiseksi FI103276B (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/670,061 US5164404A (en) 1991-03-15 1991-03-15 Hydrazone derivatives and their use

Publications (4)

Publication Number Publication Date
FI921049A0 FI921049A0 (fi) 1992-03-11
FI921049A FI921049A (fi) 1992-09-16
FI103276B1 true FI103276B1 (fi) 1999-05-31
FI103276B FI103276B (fi) 1999-05-31

Family

ID=24688827

Family Applications (1)

Application Number Title Priority Date Filing Date
FI921049A FI103276B (fi) 1991-03-15 1992-03-11 Menetelmä terapeuttisesti käyttökelpoisten bents£g|indoli-2,3-dioni-3- hydratsonijohdannaisten ja 6,7,8,9-tetrahydrobents£g|indoli-2,3-dionih ydratsonijohdannaisten valmistamiseksi

Country Status (16)

Country Link
US (1) US5164404A (fi)
EP (1) EP0503349B1 (fi)
JP (1) JP3407896B2 (fi)
KR (1) KR100192641B1 (fi)
AT (1) ATE116639T1 (fi)
AU (1) AU643877B2 (fi)
CA (1) CA2062853A1 (fi)
DE (1) DE69201068T2 (fi)
DK (1) DK0503349T3 (fi)
ES (1) ES2069330T3 (fi)
FI (1) FI103276B (fi)
GR (1) GR3015671T3 (fi)
IE (1) IE66111B1 (fi)
NO (1) NO180191C (fi)
NZ (1) NZ241752A (fi)
ZA (1) ZA921328B (fi)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9109007D0 (en) * 1991-04-26 1991-06-12 Merck Sharp & Dohme Therapeutic method
AU655643B2 (en) * 1991-07-09 1995-01-05 Neurosearch A/S Novel isatineoxime derivatives, their preparation and use
DK69693D0 (da) * 1993-06-14 1993-06-14 Neurosearch As Farven lilla
US5565580A (en) * 1994-01-27 1996-10-15 Neurosearch A/S Glutamate Antagonists
US5773434A (en) * 1995-08-30 1998-06-30 Gary A. Rogers Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia
KR19980050063A (ko) * 1996-12-20 1998-09-15 이덕림 신규한 하이드라존 유도체
AR016551A1 (es) * 1997-07-30 2001-07-25 Smithkline Beecham Corp Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos
AR016384A1 (es) * 1997-07-30 2001-07-04 Smithkline Beecham Corp Inhibidores de caspasas, composiciones farmaceuticas que comprenden dichos inhibidores de caspasas y uso de los inhibidores de caspasas para prepararun medicamento util para el tratamiento de apoptosis y desordenes asociados con excesiva actividad de la convertosa il-1 beta.
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
CN100391455C (zh) 1998-03-06 2008-06-04 阿斯特拉曾尼卡有限公司 靛红和羟吲哚衍生物的制药用途
US6492398B1 (en) 1999-03-04 2002-12-10 Smithkline Beechman Corporation Thiazoloindolinone compounds
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
AU7625500A (en) * 1999-09-30 2001-04-30 Smithkline Beecham Corporation Caspases and apoptosis
US6620818B1 (en) 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
US6589504B1 (en) 2000-09-22 2003-07-08 Pharmacia & Upjohn Company Compounds and methods for diagnosing and treating amyloid-related conditions
JP2004529110A (ja) 2001-03-06 2004-09-24 アストラゼネカ アクチボラグ 脈管損傷活性を有するインドール誘導体
BRPI0511057A (pt) * 2004-05-12 2007-11-27 Bayer Cropscience Gmbh regulação de crescimento da planta
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
CA2583764C (en) * 2004-10-25 2009-06-09 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
EP2338492A1 (en) 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
CN115304536B (zh) * 2022-07-26 2023-09-22 合肥工业大学 一种吲哚啉-2-酮化合物衍生物的制备及用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2314242A1 (de) * 1973-03-22 1974-09-26 Bayer Ag Neue 3-substituierte 2-oxo-4-hydroxy1,2,3,4-tetrahydrochinazolin-4-carbonsaeurehydrazide
US4780477A (en) * 1985-06-08 1988-10-25 Kissei Pharmaceutical Co., Ltd. Isatin compositions having anti-ulcer activities
US4988710A (en) * 1989-08-25 1991-01-29 Washington University Aryl-cycloalkyl-alkanolamines for treatment of cholinergic neurotoxins
IE69677B1 (en) * 1989-12-11 1996-10-02 Neurosearch As Isatine derivatives their preparation and use

Also Published As

Publication number Publication date
NO921000L (no) 1992-09-16
EP0503349A1 (en) 1992-09-16
KR920017650A (ko) 1992-10-21
EP0503349B1 (en) 1995-01-04
JP3407896B2 (ja) 2003-05-19
NO180191B (no) 1996-11-25
NO921000D0 (no) 1992-03-13
FI921049A (fi) 1992-09-16
ZA921328B (en) 1992-11-25
US5164404A (en) 1992-11-17
JPH0578350A (ja) 1993-03-30
ATE116639T1 (de) 1995-01-15
CA2062853A1 (en) 1992-09-16
DK0503349T3 (da) 1995-05-08
IE66111B1 (en) 1995-12-13
DE69201068T2 (de) 1995-05-11
NO180191C (no) 1997-03-05
DE69201068D1 (de) 1995-02-16
FI103276B (fi) 1999-05-31
FI921049A0 (fi) 1992-03-11
GR3015671T3 (en) 1995-07-31
KR100192641B1 (ko) 1999-06-15
ES2069330T3 (es) 1995-05-01
AU1122592A (en) 1992-09-17
AU643877B2 (en) 1993-11-25
NZ241752A (en) 1994-05-26
IE920643A1 (en) 1992-09-23

Similar Documents

Publication Publication Date Title
FI103276B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten bents[g]indoli-2,3-dioni-3-hydratsonijohdannaisten ja 6,7,8,9-tetrahydrobents[g]indoli-2,3-dionihydratsonijohdannaisten valmistamiseksi
FI890508A0 (fi) Menetelmä farmaseuttisesti aktiivisten 3-indolipalorypälehappojohdannaisten valmistamiseksi
HUP0002830A2 (hu) Indol- és 2,3-dihidroindol-származékok, előállításuk és gyógyászati alkalmazásuk
NO905320D0 (no) Fremgangsmaate for fremstilling av isatinderivater.
KR960702442A (ko) 타이로신 키나아제 억제인자로서의 치환된 β-아릴 및 β-헤테로아릴-α-시아노아크릴아미드 유도체(Substituted beta-aryl and beta-heteroaryl-alpha-cyanoacrylamide derivatives as tyrosine kinase inhibitors)
ES2246235T3 (es) Derivados de indol.
EP1331935B1 (en) Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them
FR2735129B1 (fr) Nouveaux derives de l'indole, de l'indazole et du benzisoxazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2341958T3 (es) Derivados de 2-aminobenzoilo.
PT85869B (pt) Processo para a preparacao de derivados anti-convulsivos de amino-acidos
Patel et al. 3, 4-Dihydroxyphenylalanine and related compounds
DK0633262T3 (da) Hidtil ukendte isatinoximderivater samt fremstilling og anvendelse heraf
FR2781482B1 (fr) Nouveaux derives de 8h-thieno-[2,3-b]pyrrolizine-8-one, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Legal Events

Date Code Title Description
MA Patent expired